Peter W. Jurutka

Contact:

Arizona State University 6161 East Mayo Boulevard, Phoenix, AZ 85054
Professor, Educator Scholar
Professor, Educator Scholar - Basic Medical Sciences
Faculty
Basic Medical Sciences

Education

  • PhD: Biochemistry, University of Arizona, 1993

Publications

  • Jurutka PW, di Martino O, Reshi S, Mallick S, Sausedo MA, Moen GA, Lee IJ, Ivan DJ, Krall TD, Peoples SJ, Perez A, Tromba L, Le A, Khadka I, Petros R, Savage BM, Salama E, Salama J, Ziller JW, Noh Y, Lee MY, Liu W, Welch JS, Marshall PA & Wagner CE (2022). An isochroman analog of CD3254 and allyl-, isochroman-analogs of NEt-TMN prove to be more potent retinoid-X-receptor (RXR) selective agonists than bexarotene. International Journal of Molecular Sciences. Vol. 23, 12/19/2022 - Article, Refereed Journal -
  • Grozić A, Coker K, Dussik CM, Sabir MS, Sabir Z, Bradley A, Zhang L, Park J, Yale S, Kaneko I, Hockley M, Harris LA, Lunsford TN, Sandrin TR & Jurutka PW (2022). Identification of putative transcriptomic biomarkers in irritable bowel syndrome (IBS): Differential gene expression and regulation of TPH1 and SERT by vitamin D. PLoS ONE. Vol. 17, 10/2022 - Article, Refereed Journal -
  • Khazan N, Kim KK, Hansen JN, Singh NA, Moore T, Snyder CWA, Pandita R, Strawderman M, Fujihara M, Takamura Y, Jian Y, Battaglia N, Yano N, Teramoto Y, Arnold LA, Hopson R, Kishor K, Nayak S, Ojha D, Sharon A, Ashton JM, Wang J, Milano MT, Miyamoto H, Linehan DC, Gerber SA, Kawar N, Singh AP, Tabdanov ED, Dokholyan NV, Kakuta H, Jurutka PW, Schor NF, Rowswell-Turner RB, Singh RK & Moore RG (2022). Identification of a vitamin-D receptor antagonist, MeTC7, which inhibits the growth of xenograft and transgenic tumors in vivo. J. Med. Chem. Vol. 65, 6039-6055., 04/11/2022 - Article, Refereed Journal -
  • Manhas KR, Marshall PA, Wagner CE, Jurutka PW, Mancenido MV, Debray HZ & Blattman JN (2022). Rexinoids Modulate Effector T Cell Expression of Mucosal Homing Markers CCR9 and α4β7 Integrin and Direct Their Migration In Vitro. Frontiers in Immunology. Vol. 13, 01/27/2022 - Article, Refereed Journal -
  • Reich LA, Moerland JA, Leal AS, Zhang D, Carapellucci S, Lockwood B, Jurutka PW, Marshall PA, Wagner CE & Liby KT (2022). The rexinoid V-125 reduces tumor growth in preclinical models of breast and lung cancer. Scientific Reports. Vol. 12, 01/02/2022 - Article, Refereed Journal -
Research Interests
- Nutraceuticals - Healthy Aging - Cancer
Research Summary
Dr. Jurutka's lab uses modern molecular medicine approaches to elucidate fundamental questions in human health and disease, including: effects of "nutraceuticals" on anti-aging gene expression and chemoprevention; elucidation of genetic "fingerprints" for diagnosis/treatment of IBS; rexinoid drug design/discovery for pharmaceuticals to treat cancer and Alzheimer’s disease; neurobiology of vitamin D action in autism and depression; and novel approaches in assessing the gut microbiome in IBD.